Track topics on Twitter Track topics that are important to you
Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three pre-clinical candidates, TRX518, TRX585 and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.
Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activi...
We have published hundreds of Tolerx, Inc. news stories on BioPortfolio along with dozens of Tolerx, Inc. Clinical Trials and PubMed Articles about Tolerx, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tolerx, Inc. Companies in our database. You can also find out about relevant Tolerx, Inc. Drugs and Medications on this site too.
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...